New hope for Tough-to-Treat breast cancer: testing drug on patients without genetic mutations
NCT ID NCT05522491
Summary
This study is testing whether the drug olaparib can help control recurrent triple-negative breast cancer in patients who don't have the typical BRCA gene mutations. The trial will enroll 30 women with advanced breast cancer that has returned or spread. Researchers want to see if olaparib can shrink tumors and delay cancer progression in this specific group of patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.